OTLK · NASDAQ
Outlook Therapeutics (OTLK) Stock Price & Fundamentals
Outlook Therapeutics (OTLK) closed at $641.80 on Oct 9, 2026, down 0.60% from the previous close of $645.66.
Share price, past year
1Y +23.92%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $641.80 |
| Sep 30, 2026 | $631.36 |
| Aug 31, 2026 | $665.40 |
| Jul 31, 2026 | $677.88 |
| Jun 30, 2026 | $632.60 |
| May 29, 2026 | $634.77 |
| Apr 30, 2026 | $609.14 |
| Mar 31, 2026 | $560.29 |
| Feb 27, 2026 | $549.92 |
| Jan 30, 2026 | $540.95 |
| Dec 31, 2025 | $552.63 |
| Nov 28, 2025 | $532.06 |
| Oct 31, 2025 | $523.26 |
Key statistics
- Market cap
- $120.08B
- P/E (TTM)
- —
- EPS (TTM)
- −$1.04
- Revenue (TTM)
- —
- Net income (TTM)
- −$61.12M
- Shares outstanding
- 187.1M
- Dividend yield
- —
- 52-week range
- $504.68 – $695.43
Outlook Therapeutics's market cap is $120.08B, based on a share price of $641.80 and 187.1M shares outstanding as of Jun 30, 2026.
Financials
Outlook Therapeutics reported revenue of $1.41M for fiscal 2025.
Outlook Therapeutics reported a net loss of $62.42M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Sep 30, 2025 | $1.41M | −82.7% | −$62.42M | −4,416.2% | −$1.79 | — |
| FY2019ended Sep 30, 2019 | $8.15M | +163.8% | −$34.52M | −423.8% | −$39.60 | −$32.73M |
| FY2018ended Sep 30, 2018 | $3.09M | −19.0% | −$30.09M | −974.6% | −$24.40 | −$35.82M |
| FY2017ended Sep 30, 2017 | $3.81M | +27.9% | −$38.85M | −1,019.3% | −$36.00 | −$15.80M |
| FY2016ended Sep 30, 2016 | $2.98M | −42.9% | −$53.30M | −1,788.9% | −$73.40 | — |
| FY2015ended Sep 30, 2015 | $5.22M | — | — | — | — | — |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q3 FY2025ended Jun 30, 2025 | $1.51M | −$20.15M | −$0.55 |
| Q4 FY2019ended Sep 30, 2019 | $5.85M | — | — |
| Q3 FY2019ended Jun 30, 2019 | $583.85K | — | — |
| Q2 FY2019ended Mar 31, 2019 | $641.14K | — | — |
| Q1 FY2019ended Dec 31, 2018 | $1.07M | — | — |
| Q4 FY2018ended Sep 30, 2018 | $771.89K | — | — |
| Q3 FY2018ended Jun 30, 2018 | $771.89K | — | — |
| Q2 FY2018ended Mar 31, 2018 | $771.89K | — | — |
Company profile
- Name
- Outlook Therapeutics, Inc.
- Ticker
- OTLK
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Biological Products, (No Diagnostic Substances)
- Headquarters
- 111 S. Wood Avenue, Unit #100, Iselin, NJ 08830
- Incorporated in
- DE
- Fiscal year ends
- September
- SEC CIK
- 0001649989
Recent SEC filings
- Sep 30, 2026
- Sep 18, 2026
- Aug 27, 2026
- Aug 18, 2026
- Aug 14, 2026
- Aug 14, 2026
- Aug 12, 2026
- Jul 24, 2026
Frequently asked questions
What is Outlook Therapeutics's stock price?
Outlook Therapeutics (OTLK) closed at $641.80 on Oct 9, 2026, down 0.60% from the previous close of $645.66.
What is Outlook Therapeutics's market cap?
Outlook Therapeutics's market cap is $120.08B, based on a share price of $641.80 and 187.1M shares outstanding as of Jun 30, 2026.
How much revenue does Outlook Therapeutics make?
Outlook Therapeutics reported revenue of $1.41M for fiscal 2025.
Does Outlook Therapeutics pay a dividend?
Outlook Therapeutics's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Outlook Therapeutics, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures